Feed NVSEF
NV

Novartis AG

NVSEF · OTC

$142.06 +5.42% (+$7.31)
1M -2.65%
Market Cap $262.2B
P/E Ratio 20.74x
Div. Yield 3.44%
ROE 29.64%

Bulios Fair Price

$147.44

3.8% upside

Current Price

$142.06

Undervalued Fair Value Overvalued

According to Bulios Fair Price, NVSEF is currently trading close to its fair value. How does it work?

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Piotroski F-Score Moderate
6/9
Valuation
61 /100
Fair
P/FCF 16.43x
P/E 20.74x
P/B 6.33x
Growth
64 /100
Stable
FCF growth 16.81%
EPS growth 31.82%
Book val. growth 8.07%
Profitability
100 /100
Strong
Op. margin 30.27%
Gross margin 74.29%
FCF margin 29.14%
Quality
79 /100
Excellent
ROA 10.38%
ROIC 13.75%
Asset turnover 0.45x
Debt
61 /100
Moderate
Int. coverage 12.49x
Debt/Equity 1.18x
Net debt/EBITDA 1.82x
Stability
59 /100
Moderate
EPS volatility 78.74%
Beta 0.49x
Profitable years 6

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about NVSEF
Online

About the company

Novartis AG is a Swiss multinational pharmaceutical company specializing in the development, manufacturing, and distribution of drugs and healthcare products. Founded in 1996 through the merger of Ciba-Geigy and Sandoz, the company is headquartered in Basel, Switzerland. Novartis focuses on treating a wide range of diseases, including cancer, cardiovascular conditions, neurological disorders, and more. The company is one of the largest global players in pharmaceutical research and development.

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Vasant Narasimhan

Employees

75,267

Headquarters

Basel

Upcoming events

27 OCT

Earnings

Upcoming earnings report

41d

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.